APEIRON Biologics
Apeiron Biologics is developing a potential drug candidate APN01, based on our proprietary ACE2 platform to address the growing global health threat.
Rankings by 
Национальный рейтинг
6th
in AustriaРегиональный рейтинг
363rd
in Western EuropeГлобальный рейтинг
1612th
worldwide